For anyone looking for an update, I found this article that says:
"In December the company announced the successful completion of a Phase 1 human study of FX-322, Frequency's lead progenitor cell activation drug, demonstrating its safety and tolerability. "We expect to start a Phase 2 clinical study in the second half of 2018," Lucchino said. The company has previously raised $32 million in Series A funding from CoBro Ventures, Morningside Ventures, Alexandria Real Estate Equities and other investors, and expects to begin a Series B round later this year."
Source: CNBC
Please make this successful and available A.S.A.P.
Thanks for sharing